Cytokinetics’ Phase III data sets up cardiomyopathy challenge to BMS
Cytokinetics released data on aficamten, an oral small molecule inhibitor of cardiac myosin, showing it significantly boosted exercise capacity in patients with obstructive hypertrophic cardiomyopathy.